Company / Operating Income
Perspective Therapeutics, Inc. Operating Income History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$6.4M
FY2022
5-year range
-$6.7M / -$5.1M
FY2018-FY2022
Trend
-22.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$7M in FY2020 to -$4M in FY2013.
Based on SEC 10-K filings.
-$6M in FY2022.
Improved from -$7M to -$6M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating income decreased 22.2% year-over-year.
- Peak operating income was recorded in FY2013.
- Lowest operating income in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$6.4M | -22.2% |
| FY2021 | -$5.3M | +21.9% |
| FY2020 | -$6.7M | -6.7% |
| FY2019 | -$6.3M | -24.1% |
| FY2018 | -$5.1M | -17.2% |
| FY2017 | -$4.3M | +5.5% |
| FY2016 | -$4.6M | -12.8% |
| FY2015 | -$4.1M | +0.0% |
| FY2014 | -$4.1M | -13.0% |
| FY2013 | -$3.6M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026